TABLE 6.
Activity of omadacycline and comparator antimicrobial agents when tested against bacterial isolates from urinary tract infections in the United States and Europe, SENTRY Program, 2016 to 2018
| Antimicrobial agent (no. of isolates tested) | MIC (mg/liter) |
% S/% Ra
|
|||
|---|---|---|---|---|---|
| 50% | 90% | Range | CLSI | EUCAST | |
| Staphylococcus aureus (109) | |||||
| Omadacycline | 0.12 | 025 | 0.03 to 1 | ||
| Tetracycline | ≤0.5 | ≤0.5 | ≤0.5 to >8 | 98.2/1.8 | 97.2/2.8 |
| Doxycycline | ≤0.06 | 0.12 | ≤0.06 to >8 | 99.1/0.9 | 98.2/0.9 |
| Clindamycin | ≤0.25 | >2 | ≤0.25 to >2 | 78.9/18.3 | 78.9/21.1 |
| Daptomycin | 0.25 | 0.5 | ≤0.12 to 1 | 100.0/— | 100.0/0.0 |
| Erythromycin | 0.25 | >8 | ≤0.06 to >8 | 53.2/41.3 | 53.2/43.1 |
| Levofloxacin | 0.5 | >4 | 0.06 to >4 | 52.3/47.7 | 52.3/47.7 |
| Linezolid | 1 | 2 | ≤0.12 to 4 | 100.0/0.0 | 100.0/0.0 |
| Oxacillin | 0.5 | >2 | ≤0.25 to >2 | 58.7/41.3 | 58.7/41.3 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5 to 16 | 99.1/0.9 | 99.1/0.9 |
| Vancomycin | 1 | 1 | 0.25 to 1 | 100.0/0.0 | 100.0/0.0 |
| Methicillin resistant (45) | |||||
| Omadacycline | 0.12 | 0.25 | 0.03 to 1 | ||
| Tetracycline | ≤0.5 | 1 | ≤0.5 to >8 | 95.6/4.4 | 95.6/4.4 |
| Doxycycline | ≤0.06 | 0.25 | ≤0.06 to >8 | 97.8/2.2 | 95.6/2.2 |
| Clindamycin | ≤0.25 | >2 | ≤0.25 to >2 | 55.6/42.2 | 55.6/44.4 |
| Daptomycin | 0.25 | 0.5 | 0.25 to 1 | 100.0/— | 100.0/0.0 |
| Erythromycin | >8 | >8 | ≤0.06 to >8 | 24.4/71.1 | 24.4/73.3 |
| Linezolid | 1 | 2 | 0.25 to 4 | 100.0/0.0 | 100.0/0.0 |
| Levofloxacin | >4 | >4 | 0.25 to >4 | 11.1/88.9 | 11.1/88.9 |
| Oxacillin | >2 | >2 | >2 to >2 | 0.0/100.0 | 0.0/100.0 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5 to 16 | 97.8/2.2 | 97.8/2.2 |
| Vancomycin | 1 | 1 | 0.5 to 1 | 100.0/0.0 | 100.0/0.0 |
| Enterococcus faecalis (312) | |||||
| Omadacycline | 0.12 | 0.25 | ≤0.015 to 1 | ||
| Tetracycline | >16 | >16 | ≤0.12 to >16 | 25.3/74.4 | |
| Minocycline | >8 | >8 | ≤0.06 to >8 | 33.2/53.2 | |
| Ampicillin | 1 | 1 | ≤0.5 to 2 | 100.0/— | 100.0/— |
| Daptomycin | 0.5 | 1 | ≤0.25 to 2 | 100.0/— | |
| Erythromycin | >16 | >16 | ≤0.12 to >16 | 9.3/57.9 | |
| Levofloxacin | 1 | >4 | 0.12 to >4 | 78.8/21.2 | 78.8/21.2 |
| Linezolid | 1 | 2 | 0.25 to 2 | 100.0/— | 100.0/— |
| Piperacillin-tazobactam | 4 | 8 | 2 to 16 | 100.0/— | |
| Vancomycin | 1 | 2 | 0.5 to >16 | 97.8/2.2 | 97.8/2.2 |
| Enterococcus faecium (82) | |||||
| Omadacycline | 0.06 | 0.12 | 0.03 to 1 | ||
| Tetracycline | >16 | >16 | ≤0.12 to >16 | 34.6/65.4 | |
| Minocycline | 2 | >8 | ≤0.06 to >8 | 58.3/22.9 | |
| Ampicillin | >16 | >16 | ≤0.5 to >16 | 4.9/95.1 | 4.9/95.1 |
| Daptomycin | 1 | 2 | ≤0.25 to 4 | 100.0/— | |
| Erythromycin | >16 | >16 | ≤0.12 to >16 | 8.8/82.4 | |
| Levofloxacin | >4 | >4 | 1 to >4 | 3.7/95.1 | 4.9/95.1 |
| Linezolid | 1 | 2 | 0.25 to 4 | 98.8/0.0 | 100.0/— |
| Piperacillin-tazobactam | >16 | >16 | 2 to 16 | 8.8/91.2 | |
| Vancomycin | >16 | >16 | 0.25 to >16 | 45.1/52.4 | 45.1/54.9 |
| Escherichia coli (2,872) | |||||
| Omadacycline | 0.5 | 2 | ≤0.06 to 16 | ||
| Tetracycline | 2 | >16 | ≤0.25 to >16 | 66.9/32.9 | |
| Doxycycline | 1 | >8 | 0.25 to >8 | 70.6/19.8 | |
| Minocycline | 1 | 8 | 0.12 to >32 | 86.2/8.0 | |
| Ceftazidime | 0.25 | 8 | ≤0.015 to >32 | 88.3/9.5 | 84.4/11.7 |
| Ceftriaxone | ≤0.06 | >8 | ≤0.06 to >8 | 84.0/15.8 | 84.0/15.8 |
| Gentamicin | 1 | >8 | ≤0.12 to >8 | 88.9/10.8 | 88.5/11.1 |
| Imipenem | ≤0.12 | ≤0.12 | ≤0.12 to >8 | 99.9/0.1 | 99.9/<0.1 |
| Levofloxacin | ≤0.03 | >4 | ≤0.03 to >4 | 72.4/26.6 | 72.4/26.6 |
| Piperacillin-tazobactam | 2 | 8 | ≤0.5 to >64 | 96.1/1.6 | 93.5/3.9 |
| ESBL phenotype E. colib (491) | |||||
| Omadacycline | 1 | 2 | 0.12 to 16 | ||
| Tetracycline | >16 | >16 | 0.5 to >16 | 35.8/64.0 | |
| Doxycycline | 8 | >8 | 0.25 to >8 | 46.2/29.1 | |
| Minocycline | 2 | 16 | 0.12 to >32 | 82.0/11.3 | |
| Ceftazidime | 16 | >32 | 0.25 to >32 | 31.8/55.8 | 8.8/68.2 |
| Ceftriaxone | >8 | >8 | 0.12 to >8 | 6.3/92.5 | 6.3/92.5 |
| Gentamicin | 1 | >8 | 0.25 to >8 | 71.8/27.6 | 70.1/28.2 |
| Imipenem | ≤0.12 | 0.25 | ≤0.12 to >8 | 99.4/0.4 | 99.6/0.2 |
| Levofloxacin | >4 | >4 | ≤0.03 to >4 | 23.4/75.6 | 23.4/75.6 |
| Piperacillin-tazobactam | 4 | 32 | ≤0.5 to >64 | 85.5/5.9 | 73.5/14.5 |
| Klebsiella pneumoniae (911) | |||||
| Omadacycline | 2 | 4 | 0.25 to >32 | ||
| Tetracycline | 2 | >16 | 0.5 to >16 | 72.1/24.3 | |
| Doxycycline | 2 | >8 | 0.5 to >8 | 73.5/20.5 | |
| Minocycline | 2 | 16 | 0.5 to >32 | 80.3/13.9 | |
| Ceftazidime | 0.25 | >32 | 0.03 to >32 | 75.3/22.5 | 73.4/24.7 |
| Ceftriaxone | ≤0.06 | >8 | ≤0.06 to >8 | 74.0/25.8 | 74.0/25.8 |
| Gentamicin | 0.25 | >8 | ≤0.12 to >8 | 85.6/13.8 | 84.9/14.4 |
| Imipenem | ≤0.12 | 0.5 | ≤0.12 to >8 | 94.8/4.5 | 95.5/3.4 |
| Levofloxacin | 0.06 | >4 | ≤0.03 to >4 | 76.1/18.3 | 76.1/18.3 |
| Piperacillin-tazobactam | 4 | >64 | ≤0.5 to >64 | 85.0/10.8 | 77.9/15.0 |
| ESBL phenotype K. pneumoniaeb (246) | |||||
| Omadacycline | 2 | 8 | 0.5 to >32 | ||
| Tetracycline | >16 | >16 | 0.5 to >16 | 39.4/55.3 | |
| Doxycycline | 8 | >8 | 0.5 to >8 | 43.5/43.9 | |
| Minocycline | 4 | >32 | 0.5 to >32 | 61.0/27.9 | |
| Ceftazidime | 32 | >32 | 0.5 to >32 | 8.5/83.3 | 1.6/91.5 |
| Ceftriaxone | >8 | >8 | 0.12 to >8 | 3.7/95.5 | 3.7/95.5 |
| Gentamicin | 4 | >8 | ≤0.12 to >8 | 50.0/48.0 | 47.6/50.0 |
| Imipenem | ≤0.12 | 8 | ≤0.12 to >8 | 81.3/16.7 | 83.3/12.6 |
| Levofloxacin | 4 | >4 | ≤0.03 to >4 | 30.7/60.2 | 30.7/60.2 |
| Piperacillin-tazobactam | 16 | >64 | 1 to >64 | 51.2/35.8 | 37.4/48.8 |
| Enterobacter cloacae species complex (185) | |||||
| Omadacycline | 2 | 8 | 0.25 to 32 | ||
| Tetracycline | 2 | >16 | 0.25 to >16 | 76.2/20.0 | |
| Doxycycline | 2 | >8 | 0.25 to >8 | 79.5/14.6 | |
| Minocycline | 2 | 32 | 0.25 to >32 | 71.7/16.2 | |
| Tetracycline | 2 | >16 | 0.25 to >16 | 76.2/20.0 | |
| Ceftriaxone | 0.5 | >8 | ≤0.06 to >8 | 56.2/42.7 | 56.2/42.7 |
| Ceftazidime | 0.5 | >32 | 0.12 to >32 | 60.5/38.4 | 56.2/39.5 |
| Gentamicin | 0.25 | 8 | ≤0.12 to >8 | 89.7/8.1 | 88.6/10.3 |
| Imipenem | 0.25 | 1 | ≤0.12 to 8 | 96.8/1.6 | 98.4/1.1 |
| Levofloxacin | 0.06 | >4 | ≤0.03 to >4 | 76.2/20.5 | 76.2/20.5 |
| Piperacillin-tazobactam | 4 | >64 | 0.25 to >64 | 69.2/16.8 | 62.2/30.8 |
| Enterobacter cloacae species complex, ceftazidime nonsusceptible (MIC, ≥8 mg/liter) (73) | |||||
| Omadacycline | 2 | 16 | 0.5 to 32 | ||
| Tetracycline | 2 | >16 | 1 to >16 | 60.3/37.0 | |
| Doxycycline | 2 | >8 | 0.5 to >8 | 64.4/24.7 | |
| Minocycline | 8 | 32 | 2 to >32 | 43.2/35.1 | |
| Ceftazidime | >32 | >32 | 8 to >32 | 0.0/97.3 | 0.0/100.0 |
| Ceftriaxone | >8 | >8 | 4 to >8 | 0.0/100.0 | 0.0/100.0 |
| Gentamicin | 0.5 | >8 | ≤0.12 to >8 | 75.3/20.5 | 72.6/24.7 |
| Imipenem | 0.25 | 1 | ≤0.12 to 8 | 93.2/4.1 | 95.9/2.7 |
| Levofloxacin | 0.5 | >4 | ≤0.03 to >4 | 54.8/42.5 | 54.8/42.5 |
| Piperacillin-tazobactam | 64 | >64 | 1 to >64 | 23.3/41.1 | 13.7/76.7 |
| Citrobacter spp.c (198) | |||||
| Omadacycline | 1 | 4 | 0.25 to 16 | ||
| Tetracycline | 1 | >16 | 0.5 to >16 | 84.4/12.7 | |
| Doxycycline | 1 | >8 | 0.25 to >8 | 85.9/10.1 | |
| Minocycline | 2 | 8 | 0.5 to >32 | 87.4/9.0 | |
| Ceftazidime | 0.25 | 32 | 0.06 to >32 | 87.4/12.6 | 84.3/12.6 |
| Ceftriaxone | 0.12 | >8 | ≤0.06 to >8 | 86.4/13.6 | 86.4/13.6 |
| Gentamicin | 0.5 | 1 | ≤0.12 to >8 | 93.4/5.6 | 93.4/6.6 |
| Imipenem | 0.25 | 1 | ≤0.12 to 4 | 98.5/1.0 | 99.0/0.0 |
| Levofloxacin | ≤0.03 | 1 | ≤0.03 to >4 | 89.4/6.1 | 89.4/6.1 |
| Piperacillin-tazobactam | 2 | 32 | 1 to >64 | 87.9/8.1 | 84.3/12.1 |
a
Criteria published by the Clinical and Laboratory Standards Institute (33) and The European Committee on Antimicrobial Susceptibility Testing (34). S, susceptibility; R, resistance; —, not applicable.
b
The extended-spectrum β-lactamase (ESBL) phenotype was defined as having a MIC value of ≥2 mg/liter for ceftazidime, ceftriaxone, or aztreonam (confirmatory testing was not performed).
c
Organisms include Citrobacter amalonaticus (n = 1), C. amalonaticus/Citrobacter farmeri (n = 4), Citrobacter braakii (n = 1), Citrobacter freundii (n = 28), C. freundii species complex (n = 80), Citrobacter koseri (n = 83), and Citrobacter sedlakii (n = 1).